Sphingosine kinase enzymes (SK1 and SK2) catalyse the conversion of sphingosine into sphingosine 1-phosphate and play a key role in lipid signaling and cellular responses. Mapping of isoform amino acid sequence differences for SK2 onto the recently available crystal structures of SK1 suggests that subtle structural differences exist in the foot of the lipid-binding ‘J-channel’ in SK2, the structure of which has yet to be defined by structural biology techniques. We have probed these isoform differences with a ligand series derived from the potent SK1-selective inhibitor, PF-543. Here we show how it is possible, even with relatively conservative changes in compound structure, to systematically tune the activity profile of a ligand from ca. 100-fold SK1-selective inhibition, through equipotent SK1/SK2 inhibition, to reversed 100-fold SK2 selectivity, with retention of nanomolar potency.
|Number of pages||19|
|Journal||Journal of Medicinal Chemistry|
|Early online date||19 Mar 2019|
|Publication status||Published - 11 Apr 2019|
ASJC Scopus subject areas
- Molecular Medicine
- Drug Discovery
FingerprintDive into the research topics of 'Topographical mapping of isoform-selectivity determinants for J-channel-binding inhibitors of sphingosine kinases 1 and 2'. Together they form a unique fingerprint.
David Roger Adams
- School of Engineering & Physical Sciences, Institute of Chemical Sciences - Professor
- School of Engineering & Physical Sciences - Professor
Person: Academic (Research & Teaching)